{"disease":{"id":"parkinson-s-disease-psychosis","name":"parkinson s disease psychosis"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04373317","title":"Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":358,"lead_sponsor_name":"VA Office of Research and Development","has_results":false},{"nct_id":"NCT06068465","title":"A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":248,"lead_sponsor_name":"Tasly Pharmaceutical Group Co., Ltd","has_results":false},{"nct_id":"NCT01518309","title":"An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":39,"lead_sponsor_name":"ACADIA Pharmaceuticals Inc.","has_results":true},{"nct_id":"NCT05240339","title":"Characterization and Progression of Minor Phenomena in Parkinson's Disease (PD)","phase":"","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"University of Rochester","has_results":false},{"nct_id":"NCT02762591","title":"Expanded Access of Pimavanserin for Patients With PD Psychosis","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"ACADIA Pharmaceuticals Inc.","has_results":false}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}